| Literature DB >> 30308173 |
Silke Nuber1, Molly Rajsombath1, Georgia Minakaki2, Jürgen Winkler2, Christian P Müller3, Maria Ericsson4, Barbara Caldarone5, Ulf Dettmer1, Dennis J Selkoe6.
Abstract
α-Synuclein (αS) regulates vesicle exocytosis but forms insoluble deposits in Parkinson's disease (PD). Developing disease-modifying therapies requires animal models that reproduce cardinal features of PD. We recently described a previously unrecognized physiological form of αS, α-helical tetramers, and showed that familial PD-causing missense mutations shift tetramers to aggregation-prone monomers. Here, we generated mice expressing the fPD E46K mutation plus 2 homologous E→K mutations in adjacent KTKEGV motifs. This tetramer-abrogating mutant causes phenotypes similar to PD. αS monomers accumulate at membranes and form vesicle-rich inclusions. αS becomes insoluble, proteinase K-resistant, Ser129-phosphorylated, and C-terminally truncated, as in PD. These changes affect regions controlling motor behavior, including a decrease in nigrostriatal dopaminergic neurons. The outcome is a progressive motor syndrome including tremor and gait and limb deficits partially responsive to L-DOPA. This fully penetrant phenotype indicates that tetramers are required for normal αS homeostasis and that chronically shifting tetramers to monomers may result in PD, with attendant therapeutic implications.Entities:
Keywords: L-DOPA; Parkinson’s disease; alpha-synuclein; dementia with Lewy bodies; monomer; mouse-model; neurodegeneration; tetramer; transgenic; tremor
Mesh:
Substances:
Year: 2018 PMID: 30308173 PMCID: PMC6211795 DOI: 10.1016/j.neuron.2018.09.014
Source DB: PubMed Journal: Neuron ISSN: 0896-6273 Impact factor: 17.173